Charles Rhyee
Stock Analyst at TD Cowen
(2.09)
# 3,117
Out of 5,182 analysts
78
Total ratings
45.28%
Success rate
-6.46%
Average return
Main Sectors:
Stocks Rated by Charles Rhyee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Upgrades: Buy | $15 | $10.60 | +41.51% | 5 | Mar 9, 2026 | |
| IQV IQVIA Holdings | Upgrades: Buy | $174 → $213 | $163.84 | +30.00% | 4 | Mar 9, 2026 | |
| VEEV Veeva Systems | Maintains: Buy | $380 → $300 | $160.45 | +86.97% | 5 | Mar 5, 2026 | |
| TDOC Teladoc Health | Maintains: Hold | $8 → $6 | $5.85 | +2.56% | 7 | Feb 26, 2026 | |
| CRL Charles River Laboratories International | Maintains: Buy | $251 → $235 | $171.23 | +37.24% | 7 | Feb 20, 2026 | |
| TALK Talkspace | Maintains: Buy | $6 → $9 | $5.18 | +73.75% | 3 | Feb 20, 2026 | |
| ICLR ICON Public Limited Company | Upgrades: Buy | $183 → $120 | $103.21 | +16.27% | 7 | Feb 18, 2026 | |
| MEDP Medpace Holdings | Upgrades: Hold | $462 → $419 | $421.37 | -0.56% | 7 | Feb 18, 2026 | |
| CI The Cigna Group | Maintains: Buy | $333 → $338 | $282.58 | +19.61% | 2 | Feb 9, 2026 | |
| MCK McKesson | Maintains: Buy | $1,000 → $1,012 | $828.32 | +22.18% | 5 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $45.23 | +1.70% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $2.28 | +163.16% | 8 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $400 | $310.16 | +28.97% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $99 → $100 | $78.36 | +27.62% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $183 → $225 | $202.34 | +11.20% | 3 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $27 | $27.93 | -3.33% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $100 → $50 | $6.14 | +714.33% | 3 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $56 | $5.19 | +979.00% | 2 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $360 → $280 | $7.43 | +3,668.51% | 3 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $3.47 | +1,340.92% | 2 | Jun 21, 2022 |
Fortrea Holdings
Mar 9, 2026
Upgrades: Buy
Price Target: $15
Current: $10.60
Upside: +41.51%
IQVIA Holdings
Mar 9, 2026
Upgrades: Buy
Price Target: $174 → $213
Current: $163.84
Upside: +30.00%
Veeva Systems
Mar 5, 2026
Maintains: Buy
Price Target: $380 → $300
Current: $160.45
Upside: +86.97%
Teladoc Health
Feb 26, 2026
Maintains: Hold
Price Target: $8 → $6
Current: $5.85
Upside: +2.56%
Charles River Laboratories International
Feb 20, 2026
Maintains: Buy
Price Target: $251 → $235
Current: $171.23
Upside: +37.24%
Talkspace
Feb 20, 2026
Maintains: Buy
Price Target: $6 → $9
Current: $5.18
Upside: +73.75%
ICON Public Limited Company
Feb 18, 2026
Upgrades: Buy
Price Target: $183 → $120
Current: $103.21
Upside: +16.27%
Medpace Holdings
Feb 18, 2026
Upgrades: Hold
Price Target: $462 → $419
Current: $421.37
Upside: -0.56%
The Cigna Group
Feb 9, 2026
Maintains: Buy
Price Target: $333 → $338
Current: $282.58
Upside: +19.61%
McKesson
Feb 5, 2026
Maintains: Buy
Price Target: $1,000 → $1,012
Current: $828.32
Upside: +22.18%
Jan 12, 2026
Initiates: Buy
Price Target: $46
Current: $45.23
Upside: +1.70%
Nov 10, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.28
Upside: +163.16%
Nov 10, 2025
Maintains: Buy
Price Target: $350 → $400
Current: $310.16
Upside: +28.97%
Nov 3, 2025
Maintains: Buy
Price Target: $99 → $100
Current: $78.36
Upside: +27.62%
Nov 3, 2025
Maintains: Buy
Price Target: $183 → $225
Current: $202.34
Upside: +11.20%
Nov 3, 2025
Maintains: Hold
Price Target: $30 → $27
Current: $27.93
Upside: -3.33%
Mar 23, 2023
Downgrades: Market Perform
Price Target: $100 → $50
Current: $6.14
Upside: +714.33%
Oct 20, 2022
Maintains: Outperform
Price Target: $70 → $56
Current: $5.19
Upside: +979.00%
Aug 16, 2022
Maintains: Outperform
Price Target: $360 → $280
Current: $7.43
Upside: +3,668.51%
Jun 21, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $3.47
Upside: +1,340.92%